Table 4.
Frequencies of laboratory abnormalities
| 24-week group, n/N | P | 48-week group, n/N | P | |||
|---|---|---|---|---|---|---|
| CHB | CHC | CHB | CHC | |||
| Peg-IFN associated | ||||||
| Leukopenia (<1,500 μL−1) | 0/56 (0%) | 5/103 (4.9%) | 0.163 | 1/25 (4.0%) | 4/46 (8.7%) | 0.650 |
| Neutropenia (<750 μL−1) | 9/56 (16.1%) | 23/103 (22.3%) | 0.347 | 3/25 (12.0%) | 11/46 (23.9%) | 0.351 |
| Thrombocytopenia (<50 × 1,000 μL−1) | 3/56 (5.4%) | 2/103 (1.9%) | 0.346 | 2/25 (8.0%) | 3/46 (6.5%) | 1.000 |
| ALT flare | 2/56 (3.6%) | 0/103 (0.0%) | 0.123 | 1/25 (4.0%) | 1/46 (2.2%) | 1.000 |
| PT prolonged > 3 s | 0/56 (0.0%) | 0/103 (0.0%) | 1.000 | 0/25 (0.0%) | 0/46 (0.0%) | 1.000 |
| Thyroid dysfunction | 6/56 (10.7%) | 12/103 (11.7%) | 0.859 | 2/25 (8.0%) | 7/46 (15.2%) | 0.478 |
| Ribavirin (major) or Peg associated | ||||||
| Anemia (Hb < 10 g/dL) | 1/56 (1.8%) | 33/103 (32.0%) | <0.0001* | 0/25 (0.0%) | 14/46 (30.4%) | 0.001* |
| Total bilirubin (>2 mg/dL) | 1/56 (1.8%) | 9/103 (8.7%) | 0.100 | 0/25 (0.0%) | 4/46 (8.7%) | 0.290 |
| Creatinine (>2 mg/dL) | 2/56 (3.6%) | 1/103 (1.0%) | 0.283 | 2/25 (8.0%) | 1/46 (2.2%) | 0.282 |
PT prothrombin time, Hb hemoglobin
* Statistically significant